ADC Therapeutics drops only clinical-stage drug after reviewing phase 1 leukemia data
Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole remaining clinical-stage candidate after taking a look at the early-stage data.
Zynlonta manufacturer ADC Therapeutics is continuing to prune its pipeline, calling time on its sole remaining clinical-stage candidate after taking a look at the early-stage data.
